Letrilan (Letrozole)

Letrozole blocks the aromatase enzyme, preventing the conversion of androgens into estrogens. This reduction in systemic estrogen diminishes stimulation of estrogen‑dependent tumor cells and removes negative feedback on the hypothalamic‑pituitary axis, allowing increased release of gonadotropins that support ovulation.

The dosage of Letrilan is determined individually by the prescribing clinician based on the specific indication, patient characteristics, and treatment guidelines. Patients should follow the exact regimen provided by their healthcare professional.

Letrozole is classified as pregnancy category X, meaning it is contraindicated during pregnancy because of known teratogenic risk. It is also not recommended while breastfeeding, as it may pass into milk and affect the infant.

To request Letrilan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrilan (letrozole) is a third‑generation aromatase inhibitor with a high potency and longer half‑life compared with earlier agents such as anastrozole. Clinical data suggest comparable efficacy in postmenopausal breast cancer, while some studies report slightly greater estrogen suppression, which may influence choice based on patient response and tolerability.

Letrilan should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Letrilan is taken orally, usually as a tablet swallowed whole with water. It is generally administered once daily, but the exact timing and any food considerations should follow the prescribing clinician’s instructions.

Serious adverse events include severe bone loss or osteoporosis, hepatic injury reflected by elevated liver enzymes, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should be monitored regularly for signs of these conditions.

Letrilan is contraindicated in pregnant women, individuals with known hypersensitivity to letrozole, and patients with premenopausal hormonal status when estrogen suppression is not desired. Caution is also advised for patients with severe liver disease or uncontrolled cardiovascular conditions.